Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 23, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,234.70 pence per share.
- Treasury Holdings: 497,269,158 shares (representing 9.00% of total voting rights).
- Shares in Issue: 5,528,027,770 (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 1,000,000 shares on November 23, 2007. These shares are intended to be held in Treasury. Consequently, the total number of shares in issue (excluding Treasury) remains 5,528,027,770, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,528,027,770) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (497,269,158) and its impact on total voting rights (9.00%).
- Note that this filing is a regulatory disclosure of a share buyback and does not contain operational or financial performance data for the period.